Synonym
311C90; Zolmitriptan; NSC 760383; NSC-760383; NSC760383;
IUPAC/Chemical Name
(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
InChi Key
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
InChi Code
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
SMILES Code
O=C1OC[C@H](CC2=CC3=C(NC=C3CCN(C)C)C=C2)N1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
287.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014 May 21;5:CD008616. doi: 10.1002/14651858.CD008616.pub2. Review. PubMed PMID: 24848613.
2: Tepper SJ, Chen S, Reidenbach F, Rapoport AM. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013 Sep;53 Suppl 2:62-71. doi: 10.1111/head.12181. Review. PubMed PMID: 24024604.
3: Peterlin BL, Rapoport AM. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. Expert Opin Drug Metab Toxicol. 2007 Dec;3(6):899-911. Review. PubMed PMID: 18028032.
4: Pacheco-Coronado R, McMullan PW, Galbut BH, Galbut EJ, Snell J, Schaer GL, Kavinsky CJ. Myocardial infarction after taking zolmitriptan. Yale J Biol Med. 2005 May;78(3):147-50. Review. PubMed PMID: 16464313; PubMed Central PMCID: PMC2259142.
5: Goadsby PJ, Yates R. Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache. 2006 Jan;46(1):138-49. Review. PubMed PMID: 16412161.
6: Dowson AJ, Almqvist P. Part III: the convenience of, and patient preference for, zolmitriptan orally disintegrating tablet. Curr Med Res Opin. 2005;21 Suppl 3:S13-7. Review. PubMed PMID: 16083519.
7: Gawel M, Worthington I. Intranasal zolmitriptan. Expert Opin Pharmacother. 2005 Jun;6(6):1019-24. Review. PubMed PMID: 15952929.
8: Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Zolmitriptan (Zomig). Expert Rev Neurother. 2004 Jan;4(1):33-41. Review. PubMed PMID: 15853613.
9: Boutilier AS, Gardner DM. Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report. J Clin Pharm Ther. 2003 Feb;28(1):69-72. Review. PubMed PMID: 12605621.
10: Goadsby PJ, Boes CJ. Zolmitriptan: differences from sumatriptan. Curr Med Res Opin. 2001;17 Suppl 1:s46-50. Review. PubMed PMID: 12463277.
11: Dowson AJ, Charlesworth B. Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother. 2002 Jul;3(7):993-1005. Review. PubMed PMID: 12083998.
12: Le Jeunne C. [Zolmitriptan]. Presse Med. 1999 Sep 25;28(28):1525-6. Review. French. PubMed PMID: 10526561.
13: Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: a review of its use in migraine. Drugs. 1999 Aug;58(2):347-74. Review. PubMed PMID: 10473025.
14: Morales Asín F. [Safety profile of 311C90 (zolmitriptan)]. Neurologia. 1998 Oct;13 Suppl 2:25-30. Review. Spanish. PubMed PMID: 9859692.
15: Leira R, Noya M. [Clinical efficacy of zolmitriptan in migraine]. Neurologia. 1998 Oct;13 Suppl 2:16-24. Review. Spanish. PubMed PMID: 9859691.
16: Pascual J. [Mechanism of action of zolmitriptan]. Neurologia. 1998 Oct;13 Suppl 2:9-15. Review. Spanish. PubMed PMID: 9859690.
17: Lipton RB, Stewart WF. Clinical applications of zolmitriptan (Zomig, 311C90). Cephalalgia. 1997 Oct;17 Suppl 18:53-9. Review. PubMed PMID: 9399017.
18: Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia. 1997 Oct;17 Suppl 18:21-7. Review. PubMed PMID: 9399014.
19: Martin GR. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. Review. PubMed PMID: 9399012.
20: Mathew N. Zolmitriptan. Introduction. Cephalalgia. 1997 Oct;17 Suppl 18:1-3. Review. PubMed PMID: 9399011.
